JP2013507924A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507924A5 JP2013507924A5 JP2012534356A JP2012534356A JP2013507924A5 JP 2013507924 A5 JP2013507924 A5 JP 2013507924A5 JP 2012534356 A JP2012534356 A JP 2012534356A JP 2012534356 A JP2012534356 A JP 2012534356A JP 2013507924 A5 JP2013507924 A5 JP 2013507924A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- isoform
- precursor
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 68
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 39
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 38
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 102000001708 Protein Isoforms Human genes 0.000 claims description 26
- 108010029485 Protein Isoforms Proteins 0.000 claims description 26
- 230000007704 transition Effects 0.000 claims description 25
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 20
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 18
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 11
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims description 10
- 102000009666 Cytochrome P-450 CYP2B6 Human genes 0.000 claims description 10
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 claims description 10
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 5
- 238000004949 mass spectrometry Methods 0.000 claims description 5
- 238000004885 tandem mass spectrometry Methods 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 210000001589 microsome Anatomy 0.000 claims description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000003228 microsomal effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 101000745711 Homo sapiens Cytochrome P450 3A4 Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25243009P | 2009-10-16 | 2009-10-16 | |
| US61/252,430 | 2009-10-16 | ||
| US25264809P | 2009-10-17 | 2009-10-17 | |
| US61/252,648 | 2009-10-17 | ||
| PCT/US2010/052665 WO2011047150A1 (en) | 2009-10-16 | 2010-10-14 | Mass spectrometry quantitation of p450 protein isoforms in hepatocytes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016074921A Division JP6116730B2 (ja) | 2009-10-16 | 2016-04-04 | 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507924A JP2013507924A (ja) | 2013-03-07 |
| JP2013507924A5 true JP2013507924A5 (enExample) | 2013-11-28 |
| JP5936273B2 JP5936273B2 (ja) | 2016-06-22 |
Family
ID=43876537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534356A Expired - Fee Related JP5936273B2 (ja) | 2009-10-16 | 2010-10-14 | 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量 |
| JP2016074921A Expired - Fee Related JP6116730B2 (ja) | 2009-10-16 | 2016-04-04 | 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016074921A Expired - Fee Related JP6116730B2 (ja) | 2009-10-16 | 2016-04-04 | 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US8940545B2 (enExample) |
| EP (2) | EP2862870B1 (enExample) |
| JP (2) | JP5936273B2 (enExample) |
| CA (1) | CA2777690C (enExample) |
| WO (1) | WO2011047150A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012056880A (ja) * | 2010-09-08 | 2012-03-22 | Idemitsu Kosan Co Ltd | インドロカルバゾール化合物、有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子 |
| WO2014096914A1 (en) * | 2012-12-20 | 2014-06-26 | Dh Technologies Development Pte. Ltd. | Scheduled ms3 for quantitation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1766413A2 (en) * | 2004-05-19 | 2007-03-28 | Applera Corporation | Expression quantification using mass spectrometry |
| US20080206737A1 (en) * | 2004-05-19 | 2008-08-28 | Hunter Christie L | Expression quantification using mass spectrometry |
| US20080020673A1 (en) * | 2005-03-08 | 2008-01-24 | Cara Sills | Doll having hand-assemblable costume |
| US20070092926A1 (en) * | 2005-10-14 | 2007-04-26 | Alterman Michail A | Analysis of protein isoforms using unique tryptic peptides by mass spectrometry and immunochemistry |
| JP5299956B2 (ja) * | 2008-09-29 | 2013-09-25 | 国立大学法人東北大学 | 質量分析装置を用いた代謝酵素群の一斉タンパク質定量に用いるペプチド |
-
2010
- 2010-10-14 WO PCT/US2010/052665 patent/WO2011047150A1/en not_active Ceased
- 2010-10-14 US US12/904,520 patent/US8940545B2/en active Active
- 2010-10-14 CA CA2777690A patent/CA2777690C/en not_active Expired - Fee Related
- 2010-10-14 EP EP14193907.4A patent/EP2862870B1/en active Active
- 2010-10-14 JP JP2012534356A patent/JP5936273B2/ja not_active Expired - Fee Related
- 2010-10-14 EP EP10824088.8A patent/EP2488545B1/en active Active
-
2014
- 2014-08-21 US US14/465,460 patent/US20150045256A1/en not_active Abandoned
-
2015
- 2015-01-22 US US14/602,917 patent/US9546393B2/en not_active Expired - Fee Related
-
2016
- 2016-04-04 JP JP2016074921A patent/JP6116730B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Direct and metabolism‐dependent cytochrome P450 inhibition assays for evaluating drug–drug interactions | |
| Reitsma et al. | Composition and regulation of the cellular repertoire of SCF ubiquitin ligases | |
| He et al. | Label-free absolute protein quantification with data-independent acquisition | |
| Kim et al. | High‐throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry | |
| Knights et al. | In vitro drug metabolism using liver microsomes | |
| Zhang et al. | Physiological content and intrinsic activities of 10 cytochrome P450 isoforms in human normal liver microsomes | |
| Streetman et al. | Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N‐acetyltransferase‐2, and xanthine oxidase with the “Cooperstown cocktail” | |
| Bhat et al. | Mechanism of enzyme repair by the AAA+ chaperone Rubisco activase | |
| Li et al. | High-throughput cytochrome P450 cocktail inhibition assay for assessing drug-drug and drug-botanical interactions | |
| Ghesquière et al. | Proteomics methods to study methionine oxidation | |
| Shao et al. | Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT‐SWATH mass spectrometry | |
| Zhang et al. | Correlation of cytochrome P450 oxidoreductase expression with the expression of 10 isoforms of cytochrome P450 in human liver | |
| Liu et al. | Quantitative analysis of cytochrome P450 isoforms in human liver microsomes by the combination of proteomics and chemical probe‐based assay | |
| Al Feteisi et al. | Choice of LC-MS methods for the absolute quantification of drug-metabolizing enzymes and transporters in human tissue: a comparative cost analysis | |
| Court et al. | Toward a standardized urine proteome analysis methodology | |
| Sung et al. | Systematic analysis of NDUFAF6 in complex I assembly and mitochondrial disease | |
| Williamson et al. | Quantitative protein determination for CYP induction via LC‐MS/MS | |
| JP2013507924A5 (enExample) | ||
| Gevaert et al. | Four stage liquid chromatographic selection of methionyl peptides for peptide-centric proteome analysis: the proteome of human multipotent adult progenitor cells | |
| Choi et al. | Reassessing the significance of the PAH c. 158G> A (p. Arg53His) variant in patients with hyperphenylalaninemia | |
| Mikami et al. | Selective isolation of N-blocked peptides by isocyanate-coupled resin | |
| Yoo et al. | Chemical proteomic identification of T-plastin as a novel host cell response factor inHCV infection | |
| JP6116730B2 (ja) | 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量 | |
| Xu et al. | Content and activities of UGT2B7 in human liver in vitro and predicted in vivo: a bottom-up approach | |
| Takami et al. | Identification of a novel biomarker for oxidative stress induced by hydrogen peroxide in primary human hepatocytes using the 2‐nitrobenzenesulfenyl chloride isotope labeling method |